Vakzinetherapie mit autologen, Tumorlysat-gepulsten dendritischen Zellen bei Patienten mit fortgeschrittenem Pankreaskarzinom: Abschließende Ergebnisse einer Pilotstudie

Bauer, Cassondra; Dauer, Marc; Saraj, S.; Schnurr, M.; Bauernfeind, Franz; Sterzik, Alexander; Junkmann, Jana; Jakl, Veronika; Kiefl, Rosemarie; Oduncu, Fuat; Emmerich, B.; Mayr, D.; Mussack, T.; Bruns, C; Rüttinger, Dominik; Conrad, Chester H.; Kw, Jauch; Endres, Stefan; Eigler, Andreas

doi:10.1055/s-0031-1285644

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While many studies have previously explored DC vaccination for treatment of pancreatic cancers (27,(45)(46)(47)(48)(49), few studies have investigated the role of DC vaccines for prevention of tumor development and/or recurrence. In this study, we used a murine model of PDAC to show that clinically translatable preventative intraperitoneal DC vaccination can effectively diminish tumor growth and that ADC can be used as an imaging biomarker for assessment of preventive DC vaccination therapeutic responses.…”

Section: Discussionmentioning

confidence: 99%

Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model

et al. 2020

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is the 4 th leading cause of cancer-related deaths with high recurrence after surgery due to a paucity of effective post-surgical adjuvant treatments. DC-vaccines can activate multiple anti-tumor immune responses but have not been explored for PDAC treatment. No standard delivery route has also been established for DC vaccination, but intraperitoneal (IP) delivery is of particular interest because it allows increased DC-vaccine dosage and thus migration to draining lymph nodes. Here, we for the first time showed that IP delivery of DC-vaccines prior to tumor induction decreased tumor volume and prolonged survival in a PDAC mouse model. These approaches may be readily translated clinically for PDAC treatment as both DC vaccination and IP delivery are already used at the bedside for treatment or in clinical trials.

show abstract